Regeneron: exceptional results of the monoclonal antibody that treats the covid
For the third time in about a month, another major pharmaceutical competitor has released a new COVID cure – in this case, it was Regeneron's long-awaited cocktail of COVID antibodies – which would be able to reduce the risk of covid-19 infection. 81.6%, which is slightly less than the Pfizer pill, but more than the Mercks pill. The product had been in trial for some time, but or at this stage it ended with excellent results. Trump was part of the trial and received Regeneron, recovering very quickly. Of course, stocks skyrocketed after a plunge on Pfizer's announcement.
Much has changed since then: data from phase 3 studies released by the company showed that a single dose of Regeneron could reduce the risk by 81.6% during the pre-set follow-up period (2-8), while maintaining the previously reported 81.4% risk reduction during the first month of follow-up.
During the 8-month evaluation period there were zero hospitalizations for COVID-19 in the REGEN-COV group and 6 in the placebo group. Fully human antibodies in REGEN-COV were developed to provide long-lasting protective effects without mutations or artificial sequences.
Additionally, Regeneron Pharmaceuticals announced further positive results from a Phase 3 study conducted in collaboration with the National Institute of Allergy and Infectious Diseases, which evaluated using a single investigational dose (1,200 mg administered via 4 subcutaneous injections) per patient. . The intention was to prevent COVID in uninfected individuals. The new analyzes show that REGEN-COV reduced the risk of contracting laboratory-confirmed COVID-19 (i.e. symptomatic SARS-CoV-2 infections) by 81.6% during the predetermined follow-up period (months 2-8 ), maintaining an 81.4% risk reduction during the first month after administration, first reported in the New England Journal of Medicine.
A chief scientist said Regeneron can help protect people from COVID for "many months". So it heals and prevents
"Today's new data demonstrates how a single dose of REGEN-COV can help protect people from COVID-19 for many months after administration," said Myron S. Cohen, MD, who leads monoclonal antibody efforts to the NIH-sponsored COVID prevention network. (CoVPN) and is Director of the Institute for Global Health & Infectious Diseases at the University of North Carolina at Chapel Hill. "These results demonstrate that REGEN-COV has the potential to provide lasting immunity from SARS-CoV-2 infection, a particularly important achievement for those unresponsive to COVID-19 vaccines, including immunocompromised people."
The study met its primary endpoint, reducing a patient's risk of laboratory-confirmed COVID (i.e. symptomatic SARS-CoV-2 infections) by 81.4% within 1 month of receiving REGEN-COV (p <0 , 0001). The new results released on Monday describe a predetermined analysis for the next 7 months, during which another 45 symptomatic infections occurred. During this time, REGEN-COV continued to prevent infection, requiring no additional doses.
By now we have approved treatments: why do you impose the green pass and temporary vaccinations instead of using them on a large scale?
Thanks to our Telegram channel you can stay updated on the publication of new articles of Economic Scenarios.
The article Regeneron: exceptional results of the monoclonal antibody that cures the covid comes from ScenariEconomici.it .
This is a machine translation of a post published on Scenari Economici at the URL https://scenarieconomici.it/regeneron-eccezionali-risultati-dellanticorpo-monoclonale-che-cura-il-covid/ on Mon, 08 Nov 2021 17:18:47 +0000.